{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:41:57Z","timestamp":1792708917431,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurosci"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a CAG repeat expansion mutation in the coding region of a novel gene. The mechanism of HD is unknown. Most data suggest that polyglutamine-mediated aggregation associated with expression of mutant huntingtin protein (mhtt) contributes to the pathology. However, recent studies have identified early cellular dysfunctions that preclude aggregate formation. Suppression of aggregation is accepted as one of the markers of successful therapeutic approaches. Previously, we demonstrated that tricyclic pyrone (TP) compounds efficiently inhibited formation of amyloid-\u03b2 (A\u03b2) aggregates in cell and mouse models representing Alzheimer's Disease (AD). In the present study, we aimed to determine whether TP compounds could prevent aggregation and restore early cellular defects in primary embryonic striatal neurons from animal model representing HD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>TP compounds effectively inhibit aggregation caused by mhtt in neurons and glial cells. Treatment with TP compounds also alleviated cholesterol accumulation and restored clathrin-independent endocytosis in HD neurons.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We have found that TP compounds not only blocked mhtt-induced aggregation, but also alleviated early cellular dysfunctions that preclude aggregate formation. Our data suggest TP molecules may be used as lead compounds for prevention or treatment of multiple neurodegenerative diseases including HD and AD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2202-10-73","type":"journal-article","created":{"date-parts":[[2009,7,8]],"date-time":"2009-07-08T18:14:02Z","timestamp":1247076842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tricyclic pyrone compounds prevent aggregation and reverse cellular phenotypes caused by expression of mutant huntingtin protein in striatal neurons"],"prefix":"10.1186","volume":"10","author":[{"given":"Eugenia","family":"Trushina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia T","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duy H","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,7,8]]},"reference":[{"issue":"3","key":"1077_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.tig.2004.01.008","volume":"20","author":"SH Li","year":"2004","unstructured":"Li SH, Li XJ: Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 2004, 20 (3): 146-154.","journal-title":"Trends Genet"},{"issue":"6","key":"1077_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"Huntingtin Research Collaborative Group","year":"1993","unstructured":"Huntingtin Research Collaborative Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993, 72 (6): 971-983.","journal-title":"Cell"},{"issue":"6","key":"1077_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP: Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985, 44 (6): 559-577.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"1077_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, et al.: Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996, 87 (3): 493-506.","journal-title":"Cell"},{"issue":"2","key":"1077_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/ng0298-150","volume":"18","author":"D Martindale","year":"1998","unstructured":"Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K, Singaraja R, Kazemi-Esfarjani P, Devon R, Kim SU, et al.: Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet. 1998, 18 (2): 150-154.","journal-title":"Nat Genet"},{"issue":"7","key":"1077_CR6","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/BF03401886","volume":"1","author":"MF Perutz","year":"1995","unstructured":"Perutz MF: Glutamine repeats as polar zippers: their role in inherited neurodegenerative disease. Mol Med. 1995, 1 (7): 718-721.","journal-title":"Mol Med"},{"issue":"2","key":"1077_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0968-0004(98)01350-4","volume":"24","author":"MF Perutz","year":"1999","unstructured":"Perutz MF: Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem Sci. 1999, 24 (2): 58-63.","journal-title":"Trends Biochem Sci"},{"issue":"4","key":"1077_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0896-6273(00)80581-4","volume":"21","author":"TW Kim","year":"1998","unstructured":"Kim TW, Tanzi RE: Neuronal intranuclear inclusions in polyglutamine diseases: nuclear weapons or nuclear fallout?. Neuron. 1998, 21 (4): 657-659.","journal-title":"Neuron"},{"issue":"1","key":"1077_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00401-007-0287-5","volume":"115","author":"M Yamada","year":"2008","unstructured":"Yamada M, Sato T, Tsuji S, Takahashi H: CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115 (1): 71-86.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"1077_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","volume":"90","author":"SW Davies","year":"1997","unstructured":"Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP: Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997, 90 (3): 537-548.","journal-title":"Cell"},{"issue":"4","key":"1077_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/WCO.0b013e328304b692","volume":"21","author":"E Roze","year":"2008","unstructured":"Roze E, Saudou F, Caboche J: Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol. 2008, 21 (4): 497-503.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"1077_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2202-6-1","volume":"6","author":"J Wang","year":"2005","unstructured":"Wang J, Gines S, MacDonald ME, Gusella JF: Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci. 2005, 6 (1): 1.","journal-title":"BMC Neurosci"},{"issue":"8","key":"1077_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0968-0004(03)00168-3","volume":"28","author":"P Harjes","year":"2003","unstructured":"Harjes P, Wanker EE: The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci. 2003, 28 (8): 425-433.","journal-title":"Trends Biochem Sci"},{"issue":"3","key":"1077_CR14","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.bmcl.2008.12.060","volume":"19","author":"S Rana","year":"2009","unstructured":"Rana S, Hong HS, Barrigan L, Jin LW, Hua DH: Syntheses of tricyclic pyrones and pyridinones and protection of Abeta-peptide induced MC65 neuronal cell death. Bioorg Med Chem Lett. 2009, 19 (3): 670-674.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"1077_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1471-4159.2006.03862.x","volume":"98","author":"I Maezawa","year":"2006","unstructured":"Maezawa I, Hong HS, Wu HC, Battina SK, Rana S, Iwamoto T, Radke GA, Pettersson E, Martin GM, Hua DH, et al.: A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid-beta oligomeric complexes. J Neurochem. 2006, 98 (1): 57-67.","journal-title":"J Neurochem"},{"issue":"4","key":"1077_CR16","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/j.1471-4159.2008.05866.x","volume":"108","author":"HS Hong","year":"2009","unstructured":"Hong HS, Rana S, Barrigan L, Shi A, Zhang Y, Zhou F, Jin LW, Hua DH: Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo. J Neurochem. 2009, 108 (4): 1097-1108.","journal-title":"J Neurochem"},{"issue":"21","key":"1077_CR17","doi-asserted-by":"publisher","first-page":"12171","DOI":"10.1073\/pnas.2034961100","volume":"100","author":"E Trushina","year":"2003","unstructured":"Trushina E, Heldebrant MP, Perez-Terzic CM, Bortolon R, Kovtun IV, Badger JD, Terzic A, Estevez A, Windebank AJ, Dyer RB, et al.: Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease. Proc Natl Acad Sci USA. 2003, 100 (21): 12171-12176.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"1077_CR18","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1093\/hmg\/ddl434","volume":"15","author":"E Trushina","year":"2006","unstructured":"Trushina E, Singh RD, Dyer RB, Cao S, Shah VH, Parton RG, Pagano RE, McMurray CT: Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum Mol Genet. 2006, 15 (24): 3578-3591.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"1077_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","volume":"23","author":"JG Hodgson","year":"1999","unstructured":"Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, et al.: A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999, 23 (1): 181-192.","journal-title":"Neuron"},{"issue":"1\u20132","key":"1077_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0169-328X(94)90092-2","volume":"26","author":"BL Sopher","year":"1994","unstructured":"Sopher BL, Fukuchi K, Smith AC, Leppig KA, Furlong CE, Martin GM: Cytotoxicity mediated by conditional expression of a carboxyl-terminal derivative of the beta-amyloid precursor protein. Brain Res Mol Brain Res. 1994, 26 (1\u20132): 207-217.","journal-title":"Brain Res Mol Brain Res"},{"issue":"1\u20132","key":"1077_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12031-002-0011-9","volume":"19","author":"LW Jin","year":"2002","unstructured":"Jin LW, Hua DH, Shie FS, Maezawa I, Sopher B, Martin GM: Novel tricyclic pyrone compounds prevent intracellular APP C99-induced cell death. J Mol Neurosci. 2002, 19 (1\u20132): 57-61.","journal-title":"J Mol Neurosci"},{"key":"1077_CR22","doi-asserted-by":"crossref","unstructured":"Hua DH, Huang X, Tamura M, Chen Y, Woltkamp M, Jin L, Perchellet EM, Perchellet J, Chiang PK, Namatame I: Syntheses and bioactivities of tricyclic pyrones. Tetrahedron. 2003, 4795-4803. 59","DOI":"10.1016\/S0040-4020(03)00687-2"},{"issue":"1","key":"1077_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1582-4934.2007.00148.x","volume":"12","author":"Q Gong","year":"2008","unstructured":"Gong Q, Huntsman C, Ma D: Clathrin-independent internalization and recycling. J Cell Mol Med. 2008, 12 (1): 126-144.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"1077_CR24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1152\/physrev.1997.77.3.759","volume":"77","author":"S Mukherjee","year":"1997","unstructured":"Mukherjee S, Ghosh RN, Maxfield FR: Endocytosis. Physiol Rev. 1997, 77 (3): 759-803.","journal-title":"Physiol Rev"},{"issue":"8","key":"1077_CR25","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1091\/mbc.E02-12-0809","volume":"14","author":"RD Singh","year":"2003","unstructured":"Singh RD, Puri V, Valiyaveettil JT, Marks DL, Bittman R, Pagano RE: Selective caveolin-1-dependent endocytosis of glycosphingolipids. Mol Biol Cell. 2003, 14 (8): 3254-3265.","journal-title":"Mol Biol Cell"},{"issue":"5 Pt 1","key":"1077_CR26","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1083\/jcb.97.5.1592","volume":"97","author":"N Simionescu","year":"1983","unstructured":"Simionescu N, Lupu F, Simionescu M: Rings of membrane sterols surround the openings of vesicles and fenestrae, in capillary endothelium. J Cell Biol. 1983, 97 (5 Pt 1): 1592-1600.","journal-title":"J Cell Biol"},{"issue":"1","key":"1077_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/npp.2008.115","volume":"34","author":"EB De Souza","year":"2009","unstructured":"De Souza EB, Cload ST, Pendergrast PS, Sah DW: Novel therapeutic modalities to address nondrugable protein interaction targets. Neuropsychopharmacology. 2009, 34 (1): 142-158.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1077_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/npp.2008.151","volume":"34","author":"LL Blazer","year":"2009","unstructured":"Blazer LL, Neubig RR: Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. Neuropsychopharmacology. 2009, 34 (1): 126-141.","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"1077_CR29","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/iub.117","volume":"60","author":"H Ecroyd","year":"2008","unstructured":"Ecroyd H, Carver JA: Unraveling the mysteries of protein folding and misfolding. IUBMB Life. 2008, 60 (12): 769-774.","journal-title":"IUBMB Life"},{"issue":"5","key":"1077_CR30","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","volume":"81","author":"J Nasir","year":"1995","unstructured":"Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, Borowski A, Marth JD, Phillips AG, Hayden MR: Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995, 81 (5): 811-823.","journal-title":"Cell"},{"issue":"6555","key":"1077_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/378403a0","volume":"378","author":"Y Trottier","year":"1995","unstructured":"Trottier Y, Lutz Y, Stevanin G, Imbert G, Devys D, Cancel G, Saudou F, Weber C, David G, Tora L, et al.: Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature. 1995, 378 (6555): 403-406.","journal-title":"Nature"},{"issue":"3","key":"1077_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1385\/MN:28:3:259","volume":"28","author":"A Reiner","year":"2003","unstructured":"Reiner A, Dragatsis I, Zeitlin S, Goldowitz D: Wild-type huntingtin plays a role in brain development and neuronal survival. Mol Neurobiol. 2003, 28 (3): 259-276.","journal-title":"Mol Neurobiol"},{"issue":"Pt 5","key":"1077_CR33","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1242\/jcs.115.5.941","volume":"115","author":"G Hoffner","year":"2002","unstructured":"Hoffner G, Kahlem P, Djian P: Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. J Cell Sci. 2002, 115 (Pt 5): 941-948.","journal-title":"J Cell Sci"},{"issue":"1\u20132","key":"1077_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0169-328X(97)00205-2","volume":"51","author":"T Tukamoto","year":"1997","unstructured":"Tukamoto T, Nukina N, Ide K, Kanazawa I: Huntington's disease gene product, huntingtin, associates with microtubules in vitro. Brain Res Mol Brain Res. 1997, 51 (1\u20132): 8-14.","journal-title":"Brain Res Mol Brain Res"},{"key":"1077_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0076-6879(07)38017-8","volume":"438","author":"A Pal","year":"2008","unstructured":"Pal A, Severin F, Hopfner S, Zerial M: Regulation of endosome dynamics by Rab5 and Huntingtin-HAP40 effector complex in physiological versus pathological conditions. Methods Enzymol. 2008, 438: 239-257.","journal-title":"Methods Enzymol"},{"issue":"18","key":"1077_CR36","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1128\/MCB.24.18.8195-8209.2004","volume":"24","author":"E Trushina","year":"2004","unstructured":"Trushina E, Dyer RB, Badger JD, Ure D, Eide L, Tran DD, Vrieze BT, Legendre-Guillemin V, McPherson PS, Mandavilli BS, et al.: Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol. 2004, 24 (18): 8195-8209.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"1077_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0896-6273(03)00569-5","volume":"40","author":"G Szebenyi","year":"2003","unstructured":"Szebenyi G, Morfini GA, Babcock A, Gould M, Selkoe K, Stenoien DL, Young M, Faber PW, MacDonald ME, McPhaul MJ, et al.: Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron. 2003, 40 (1): 41-52.","journal-title":"Neuron"},{"issue":"1","key":"1077_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0896-6273(03)00594-4","volume":"40","author":"S Gunawardena","year":"2003","unstructured":"Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, Gordesky-Gold B, Sintasath L, Bonini NM, Goldstein LS: Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron. 2003, 40 (1): 25-40.","journal-title":"Neuron"},{"issue":"4","key":"1077_CR39","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.pneurobio.2006.11.004","volume":"83","author":"R Truant","year":"2007","unstructured":"Truant R, Atwal RS, Burtnik A: Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease. Prog Neurobiol. 2007, 83 (4): 211-227.","journal-title":"Prog Neurobiol"},{"issue":"6555","key":"1077_CR40","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/378398a0","volume":"378","author":"XJ Li","year":"1995","unstructured":"Li XJ, Li SH, Sharp AH, Nucifora FC, Schilling G, Lanahan A, Worley P, Snyder SH, Ross CA: A huntingtin-associated protein enriched in brain with implications for pathology. Nature. 1995, 378 (6555): 398-402.","journal-title":"Nature"},{"issue":"14","key":"1077_CR41","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1002\/jnr.21326","volume":"85","author":"J Rong","year":"2007","unstructured":"Rong J, Li SH, Li XJ: Regulation of intracellular HAP1 trafficking. J Neurosci Res. 2007, 85 (14): 3025-3029.","journal-title":"J Neurosci Res"},{"issue":"7","key":"1077_CR42","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.7164\/antibiotics.46.1168","volume":"46","author":"S Omura","year":"1993","unstructured":"Omura S, Tomoda H, Kim YK, Nishida H: Pyripyropenes, highly potent inhibitors of acyl-CoA:cholesterol acyltransferase produced by Aspergillus fumigatus. J Antibiot (Tokyo). 1993, 46 (7): 1168-1169.","journal-title":"J Antibiot (Tokyo)"},{"issue":"3","key":"1077_CR43","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/00041433-200106000-00008","volume":"12","author":"TY Chang","year":"2001","unstructured":"Chang TY, Chang CC, Lin S, Yu C, Li BL, Miyazaki A: Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2. Curr Opin Lipidol. 2001, 12 (3): 289-296.","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"1077_CR44","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nn0403-345","volume":"6","author":"L Puglielli","year":"2003","unstructured":"Puglielli L, Tanzi RE, Kovacs DM: Alzheimer's disease: the cholesterol connection. Nat Neurosci. 2003, 6 (4): 345-351.","journal-title":"Nat Neurosci"},{"issue":"1","key":"1077_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0896-6273(03)00840-7","volume":"41","author":"B Wolozin","year":"2004","unstructured":"Wolozin B: Cholesterol and the biology of Alzheimer's disease. Neuron. 2004, 41 (1): 7-10.","journal-title":"Neuron"},{"issue":"10","key":"1077_CR46","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/ncb1001-905","volume":"3","author":"L Puglielli","year":"2001","unstructured":"Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM: Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol. 2001, 3 (10): 905-912.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"1077_CR47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.neuron.2004.08.043","volume":"44","author":"B Hutter-Paier","year":"2004","unstructured":"Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, et al.: The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron. 2004, 44 (2): 227-238.","journal-title":"Neuron"},{"issue":"1","key":"1077_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbalip.2003.12.005","volume":"1636","author":"K Sugimoto","year":"2004","unstructured":"Sugimoto K, Tsujita M, Wu C-A, Suzuki K, Yokoyama S: An inhibitor of acylCoA: cholesterol acyltransferase increases expression of ATP-binding cassette transporter A1 and thereby enhances the ApoA-I-mediated release of cholesterol from macrophages. Biochim Biophys Acta. 2004, 1636 (1): 69-76.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"1077_CR49","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/hep.20439","volume":"40","author":"JJ Repa","year":"2004","unstructured":"Repa JJ, Buhman KK, Farese RV, Dietschy JM, Turley SD: ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse: Impact on hepatic cholesterol homeostasis. Hepatology. 2004, 40 (5): 1088-1097.","journal-title":"Hepatology"},{"issue":"2","key":"1077_CR50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF02290678","volume":"20","author":"GT Barnes","year":"1994","unstructured":"Barnes GT, Duyao MP, Ambrose CM, McNeil S, Persichetti F, Srinidhi J, Gusella JF, MacDonald ME: Mouse Huntington's disease gene homolog (Hdh). Somat Cell Mol Genet. 1994, 20 (2): 87-97.","journal-title":"Somat Cell Mol Genet"},{"issue":"5","key":"1077_CR51","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/jnr.490350513","volume":"35","author":"GJ Brewer","year":"1993","unstructured":"Brewer GJ, Torricelli JR, Evege EK, Price PJ: Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res. 1993, 35 (5): 567-576.","journal-title":"J Neurosci Res"}],"container-title":["BMC Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2202-10-73.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T07:02:48Z","timestamp":1630479768000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurosci.biomedcentral.com\/articles\/10.1186\/1471-2202-10-73"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,8]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1077"],"URL":"https:\/\/doi.org\/10.1186\/1471-2202-10-73","relation":{},"ISSN":["1471-2202"],"issn-type":[{"value":"1471-2202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,8]]},"assertion":[{"value":"18 March 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"73"}}